<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical management of gastroesophageal reflux disease in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical management of gastroesophageal reflux disease in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Medical management of gastroesophageal reflux disease in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Kahrilas, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas J Talley, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The passage of gastric contents into the esophagus (gastroesophageal reflux) is a normal physiologic process. Most episodes are brief and do not cause symptoms, esophageal injury, or other complications. Gastroesophageal reflux becomes a disease when it either causes macroscopic damage to the esophagus or causes symptoms.</p><p>This topic will review the initial management of gastroesophageal reflux disease (GERD) and management of patients with recurrent GERD when treatment is discontinued. Our recommendations are largely consistent with the American Gastroenterological Association and the American College of Gastroenterology guidelines [<a href="#rid1">1,2</a>]. The evaluation and management of refractory GERD and the role of surgery and endoscopic therapy in patients with GERD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2278.html" rel="external">"Surgical treatment of gastroesophageal reflux in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2254.html" rel="external">"Radiofrequency treatment for gastroesophageal reflux disease"</a>.)</p><p class="headingAnchor" id="H671602654"><span class="h1">PRETREATMENT EVALUATION</span></p><p class="headingAnchor" id="H3626252909"><span class="h2">Assessment of clinical severity</span><span class="headingEndMark"> — </span>The frequency and severity of symptoms can guide the management of GERD. Symptoms are considered mild or moderate/severe based on whether they impair quality of life. Symptoms may be intermittent (less than two episodes per week) or frequent (two or more episodes per week). (See  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H4110753911"><span class="h2">Are there indications for upper endoscopy?</span><span class="headingEndMark"> — </span>Upper endoscopy is not required in the presence of typical GERD symptoms of heartburn or regurgitation [<a href="#rid2">2</a>]. We recommend an upper endoscopy if the diagnosis of GERD is unclear and to evaluate alarm features or abnormal imaging if not performed within the last three months. Upper endoscopy should also be performed to screen for Barrett’s esophagus in patients with risk factors. Patients with GERD should receive empiric acid suppressive therapy, even if additional evaluation with an upper endoscopy is indicated. (See  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults", section on 'Evaluation in selected patients'</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120419">(Related Pathway(s):  <a class="utd-content-120419" href="/pathway/120419?topicRef=2258&amp;source=see_link">Gastroesophageal reflux disease: Identification of adults who require upper endoscopy</a>.)</span></p><p class="headingAnchor" id="H102009617"><span class="h1">INITIAL MANAGEMENT</span></p><p class="headingAnchor" id="H1576013433"><span class="h2">Overall approach</span><span class="headingEndMark"> — </span>Our management approach to patients with gastroesophageal reflux disease (GERD) is based on the frequency and severity of symptoms and the presence of erosive esophagitis or Barrett’s esophagus on upper endoscopy, if previously performed  (<a class="graphic graphic_algorithm graphicRef116964" data-inline-graphics="116964" href="/z/d/graphic/116964.html" rel="external">algorithm 1</a>). (See <a class="local">'Pretreatment evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults", section on 'Endoscopic findings'</a>.)</p><p>In patients with mild and intermittent symptoms (fewer than two episodes per week) and no evidence of erosive esophagitis, we suggest step-up therapy for GERD. The step-up approach involves incrementally increasing the potency of therapy until symptom control is achieved. In patients who are naïve to treatment, we initially recommend lifestyle and dietary modification and, as needed, low-dose histamine 2 receptor antagonists (H2RAs)  (<a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>). We suggest concomitant antacids and/or sodium alginate as needed if symptoms occur less than once a week. For patients with continued symptoms despite these measures, we increase the dose of H2RAs to standard dose, twice daily for a minimum of two weeks. Further increases in the dose of H2RA, prolonging the course of treatment, or switching to another H2RA is unlikely to control symptoms [<a href="#rid3">3,4</a>]. Therefore, if symptoms of GERD persist, we discontinue H2RAs and initiate once-daily proton pump inhibitors (PPIs) at a low dose and then increase to standard doses if required  (<a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>). We make incremental changes in therapy at four- to eight-week intervals. Once symptoms are controlled, treatment should be continued for at least eight weeks.</p><p>In patients with erosive esophagitis, frequent symptoms (two or more episodes per week), and/or severe symptoms that impair quality of life, we use step-down therapy in order to optimize symptom relief. The step-down approach starts with potent antisecretory agents and then involves incrementally, decreasing the potency of therapy until breakthrough symptoms define the treatment necessary for symptom control. We begin with standard-dose PPI once daily for eight weeks in addition to lifestyle and dietary modification  (<a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>). We subsequently decrease acid suppression to low-dose PPIs and then to H2RAs if patients have mild or intermittent symptoms. We discontinue acid suppression in all asymptomatic patients with the exception of patients with severe erosive esophagitis or Barrett's esophagus, in whom we suggest maintenance PPI therapy. (See <a class="local">'Duration of acid suppression'</a> below.)</p><p>Patients with GERD may be managed with a step-up or step-down approach to therapy. While the optimal strategy is controversial, both have advantages [<a href="#rid5">5-7</a>]. The step-up approach minimizes the use of PPIs and their associated costs and side effects, whereas step-down therapy provides faster symptom relief. (See  <a class="medical medical_review" href="/z/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H2"><span class="h2">Lifestyle and dietary modification</span><span class="headingEndMark"> — </span>Although several lifestyle and dietary modifications have been used in clinical practice, a systematic review of 16 randomized trials that evaluated the impact of these measures on GERD concluded that only weight loss and elevation of the head end of the bed improved esophageal pH-metry and/or GERD symptoms [<a href="#rid8">8-13</a>].</p><p>We suggest the following lifestyle and dietary measures [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss for patients with GERD who are overweight or have had recent weight gain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevation of the head of the bed in individuals with nocturnal or laryngeal symptoms (eg, cough, hoarseness, throat clearing). This can be achieved either by putting six- to eight-inch blocks under the legs at the head of the bed or a Styrofoam wedge under the mattress. We also suggest a corollary to this recommendation: refraining from assuming a supine position after meals and avoidance of meals two to three hours before bedtime [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest selective elimination of dietary triggers (caffeine, chocolate, spicy foods, food with high fat content, carbonated beverages, and peppermint) in patients who note correlation with GERD symptoms and an improvement in symptoms with elimination. In a prospective study of 48,308 women, intake of coffee, tea, and soda, but not milk, water, or juice were associated with a modest and dose-dependent increase in risk of GERD symptoms (HR 1.34, 1.26 and 1.29) [<a href="#rid16">16</a>]. Substitution of two servings per day of coffee, tea, or soda with water was associated with a small reduction in GERD symptoms (HR, 0.96; tea HR, 0.96; and soda HR, 0.92, respectively).</p><p></p><p>Other measures that have a physiologic basis but have not consistently been demonstrated to improve reflux symptoms include [<a href="#rid8">8,15,17,18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of tight-fitting garments to prevent increasing intragastric pressure and the gastroesophageal pressure gradient. (See  <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">"Pathophysiology of reflux esophagitis", section on 'Gastroesophageal junction incompetence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Promotion of salivation through oral lozenges/chewing gum to neutralize refluxed acid and increase the rate of esophageal acid clearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of tobacco and alcohol, as both reduce lower esophageal sphincter pressure and smoking also diminishes salivation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal breathing exercises to strengthen the antireflux barrier of the lower esophageal sphincter.</p><p></p><p>In a prospective study of 42,955 females, the risk for GERD symptoms was significantly lower for those with five antireflux lifestyle factors as compared with females without adherence to antireflux lifestyle factors (HR 0.50; 95% CI 0.42-0.59) [<a href="#rid19">19</a>]. These measures included eating a diet rich in whole grains, vegetables, and fruits; maintaining a healthy body weight; not smoking; exercising for 30 minutes per day; and drinking no more than two cups of soda, coffee, or tea per day. Up to 40 percent of weekly GERD symptoms could be prevented through five dietary and lifestyle factors. The decreased risk of GERD symptoms associated with these measures was observed even among regular users of PPIs and H2RAs.</p><p class="headingAnchor" id="H131909694"><span class="h2">Mild and intermittent symptoms</span></p><p class="headingAnchor" id="H102011552"><span class="h3">Antacids</span><span class="headingEndMark"> — </span>As antacids do not prevent GERD, their role is limited to intermittent (on-demand) use for relief of mild GERD symptoms that occur less than once a week [<a href="#rid4">4</a>]. Antacids usually contain a combination of a magnesium salt, aluminum hydroxide, or <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> (eg, <a class="drug drug_general" data-topicid="8614" href="/z/d/drug information/8614.html" rel="external">aluminum hydroxide-magnesium hydroxide</a>), which neutralize gastric pH, thereby decreasing the exposure of the esophageal mucosa to gastric acid during episodes of reflux. Antacids begin to provide relief of heartburn within five minutes, but have a short duration of effect of 30 to 60 minutes. The side effects of antacids are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/32.html" rel="external">"Antiulcer medications: Mechanism of action, pharmacology, and side effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H671603168"><span class="h3">Surface agents and alginates</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">Sucralfate</a> (aluminum sucrose sulfate), a surface agent, adheres to the mucosal surface, promotes healing, and protects from peptic injury by mechanisms that are incompletely understood. However, given the short duration of action and limited efficacy as compared with PPIs, the use of sucralfate is limited to the management of GERD in pregnancy [<a href="#rid2">2,20</a>]. (See <a class="local">'Pregnancy and lactation'</a> below.)</p><p>Sodium alginate is a polysaccharide derived from seaweed that forms a viscous gum that floats within the stomach and neutralizes the postprandial acid pocket in the proximal stomach [<a href="#rid21">21</a>]. Studies evaluating the efficacy of alginates on GERD symptoms and esophageal acid exposure suggest this may be beneficial, especially for postprandial symptoms in individuals with relatively mild reflux disease [<a href="#rid22">22-25</a>]. They are also used as add-on therapy in patients with refractory GERD. (See  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults", section on 'Residual acid reflux'</a>.)</p><p class="headingAnchor" id="H2373417761"><span class="h3">Histamine 2 receptor antagonist</span><span class="headingEndMark"> — </span>Histamine 2 receptor antagonists (H2RAs) decrease the secretion of acid by inhibiting the histamine 2 receptor on the gastric parietal cell. However, the development of tachyphylaxis within two to six weeks of initiation of H2RAs limits their use in the management of GERD [<a href="#rid26">26</a>]. (See <a class="local">'Mild and intermittent symptoms'</a> above.)</p><p>In contrast to antacids, H2RAs have a slower onset of action, reaching peak concentrations 2.5 hours after dosing, but a significantly longer duration of action of 4 to 10 hours [<a href="#rid27">27</a>]. H2RAs are also more effective in decreasing the frequency and severity of heartburn symptoms as compared with antacids and placebo.</p><p>However, H2RAs have limited efficacy in patients with erosive esophagitis. While mucosal healing rates in patients with mild erosive esophagitis are 10 to 24 percent higher with H2RA therapy as compared with placebo, H2RAs are ineffective in patients with severe esophagitis [<a href="#rid28">28-30</a>].</p><p class="headingAnchor" id="H671603146"><span class="h2">Severe or frequent symptoms or erosive esophagitis</span><span class="headingEndMark"> — </span>We use step-down therapy in patients with erosive esophagitis, frequent symptoms (two or more episodes per week), and/or severe symptoms that impair quality of life in order to optimize symptom relief. We begin with standard-dose PPI once daily for eight weeks in addition to lifestyle and dietary modification  (<a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>). (See <a class="local">'Lifestyle and dietary modification'</a> above.)</p><p class="headingAnchor" id="H102009998"><span class="h3">Proton pump inhibitors</span><span class="headingEndMark"> — </span>PPIs should be used in patients who fail twice-daily H2RA therapy and in patients with erosive esophagitis and/or frequent (two or more episodes per week) or severe symptoms of GERD that impair quality of life. (See <a class="local">'Mild and intermittent symptoms'</a> above and  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults", section on 'Endoscopic findings'</a>.)</p><p>PPIs are the most potent inhibitors of gastric acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium (H-K) ATPase pump. PPIs are most effective when taken 30 to 60 minutes before the first meal of the day because the amount of H-K-ATPase present in the parietal cell is greatest after a prolonged fast. PPIs should be administered daily rather than on demand because continuous therapy provided better symptom control, quality of life, and higher endoscopic remission rates [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/z/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Dose and timing of administration'</a>.)</p><p>PPIs at standard doses for eight weeks relieve symptoms of GERD and heal esophagitis in up to 86 percent of patients with erosive esophagitis [<a href="#rid27">27,33</a>]. There are no major differences in efficacy among PPIs and no consistent increase in symptom resolution or esophagitis healing rates between different doses or dosing regimens of PPI therapy [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Pharmacology'</a>.)</p><p>As compared with H2RAs, PPIs provide faster symptom relief and are more effective in relieving symptoms of GERD [<a href="#rid34">34-36</a>]. In a meta-analysis of 34 trials that included 1314 individuals, PPIs were significantly more effective than H2RAs in relieving heartburn in patients treated empirically for GERD and in patients with nonerosive reflux disease on upper endoscopy (relative risk [RR] 0.66 and 0.78, respectively) [<a href="#rid36">36</a>]. PPIs are also more effective than H2RAs in healing erosive esophagitis, regardless of the severity of esophagitis and the dose and duration of treatment [<a href="#rid28">28,37,38</a>].</p><p>Limitations of PPIs include a higher cost as compared with H2RAs, and potential side effects. The side effects associated with PPIs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H431480973"><span class="h3">Repeat endoscopy for severe erosive esophagitis</span><span class="headingEndMark"> — </span>Patients with severe erosive esophagitis (Los Angeles classification Grade C and D) on initial endoscopy should undergo a follow-up endoscopy after a two-month course of PPI therapy to assess healing and rule out Barrett's esophagus. Repeat endoscopy after this follow-up examination is not indicated in the absence of Barrett's esophagus unless patients have bleeding, dysphagia, or a significant change in symptoms while on effective therapy for GERD. (See  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults", section on 'Endoscopic findings'</a> and  <a class="medical medical_review" href="/z/d/html/2236.html" rel="external">"Barrett's esophagus: Surveillance and management", section on 'Surveillance'</a>.)</p><p class="headingAnchor" id="H3511387647"><span class="h1">SUBSEQUENT MANAGEMENT</span></p><p class="headingAnchor" id="H1097903516"><span class="h2">PPI refractory symptoms</span><span class="headingEndMark"> — </span>Patients who fail to respond to once-daily proton pump inhibitor (PPI) therapy are considered to have refractory reflux-like symptoms. We perform a diagnostic endoscopy along with an ambulatory esophageal pH-metry study, ideally after PPIs are stopped for at least two weeks, in patients whose reflux-like symptoms do not respond adequately to an eight-week empiric trial of PPIs [<a href="#rid2">2,39</a>]. This helps phenotype them as refractory GERD, reflux hypersensitivity, or functional heartburn [<a href="#rid40">40</a>]. The management of patients with refractory GERD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults", section on 'Initial assessment'</a>.)</p><p class="headingAnchor" id="H3513010565"><span class="h2">Duration of acid suppression</span></p><p class="headingAnchor" id="H2804337258"><span class="h3">Patients with erosive esophagitis or Barrett's esophagus</span><span class="headingEndMark"> — </span>Patients with erosive esophagitis or Barrett's esophagus require maintenance acid suppression with a PPI at standard dose as they are likely to have recurrent symptoms and complications if acid suppression is decreased or discontinued [<a href="#rid31">31,41-44</a>]. The rationale for continuing PPI therapy in patients with Barrett's esophagus is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2236.html" rel="external">"Barrett's esophagus: Surveillance and management", section on 'Management of acid reflux'</a>.)</p><p class="headingAnchor" id="H2539689075"><span class="h3">Patients without erosive esophagitis and Barrett's esophagus</span><span class="headingEndMark"> — </span>PPIs should be prescribed at the lowest dose and for the shortest duration appropriate to the condition being treated [<a href="#rid2">2,41</a>]. In patients whose classic GERD symptoms respond to an eight-week empiric trial of PPIs, an attempt should be made to discontinue treatment. In patients on PPIs for longer than six months, we taper the PPI dose before discontinuing it and use H2RAs for mild or intermittent symptoms. We discontinue acid suppression completely in asymptomatic patients. (See  <a class="medical medical_review" href="/z/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Discontinuing PPIs'</a>.)</p><p class="headingAnchor" id="H3390834743"><span class="h2">Recurrent symptoms</span><span class="headingEndMark"> — </span>Approximately two-thirds of patients with nonerosive reflux disease relapse when acid suppression is discontinued. Patients with recurrent symptoms should be managed with acid suppressive therapy with the medication and dose used to previously control symptoms [<a href="#rid42">42,45,46</a>]. If necessary for symptom control, therapy may be stepped up to medications of increasing potency as with initial therapy  (<a class="graphic graphic_algorithm graphicRef116964" href="/z/d/graphic/116964.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with recurrent symptoms ≥3 months after discontinuing acid suppression, we use repeated eight-week courses of acid suppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with recurrent symptoms &lt;3 months of discontinuing acid suppression who have not previously undergone an upper endoscopy, we perform an upper endoscopy to rule out other etiologies and complications of GERD. Patients with recurrent symptoms within three months of discontinuing acid suppression require long-term maintenance therapy with a PPI for acid suppression. However, PPI therapy should be used at the lowest effective dose necessary to control GERD symptoms.</p><p></p><p class="bulletIndent1">The role of surgery and endoscopic therapy in patients with GERD who cannot tolerate long-term PPIs or want to discontinue therapy due to concerns about long-term side effects are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/2278.html" rel="external">"Surgical treatment of gastroesophageal reflux in adults", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/2254.html" rel="external">"Radiofrequency treatment for gastroesophageal reflux disease"</a>.)</p><p></p><p class="headingAnchor" id="H1981887605"><span class="h2">Indications for referral</span><span class="headingEndMark"> — </span>Referral to a subspecialist is warranted for patients who fail to respond to once daily PPI therapy (refractory GERD), and patients who cannot tolerate long-term PPIs or want to discontinue therapy. (See  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2278.html" rel="external">"Surgical treatment of gastroesophageal reflux in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2254.html" rel="external">"Radiofrequency treatment for gastroesophageal reflux disease"</a>.)</p><p class="headingAnchor" id="H3035363942"><span class="h2">No role for empiric eradication of Helicobacter pylori</span><span class="headingEndMark"> — </span>It is uncertain whether chronic acid suppression with PPIs increases the risk for atrophic gastritis in patients with <em>H. pylori</em>. Therefore, routine screening for <em>H. pylori </em>infection and empiric eradication of <em>H. pylori</em> are not recommended in patients with GERD [<a href="#rid14">14</a>].</p><p>However, if <em>H. pylori</em> is diagnosed in the setting of GERD, eradication of <em>H. pylori</em> has been associated with an improvement of symptoms in patients with antral-predominant gastritis. The treatment of <em>H. pylori</em> in the setting of GERD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/11.html" rel="external">"Helicobacter pylori and gastroesophageal reflux disease"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">PREGNANCY AND LACTATION</span><span class="headingEndMark"> — </span>Initial management of gastroesophageal reflux disease (GERD) in pregnancy consists of lifestyle and dietary modification (eg, elevation of the head end of the bed, avoidance of dietary triggers). In patients with persistent symptoms, pharmacologic therapy should begin with antacids, alginates, or <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a> (1 g orally three times daily). In patients who fail to respond, similar to nonpregnant patients, histamine 2 receptor antagonists (H2RAs) and then proton pump inhibitors (PPIs) should be used to control symptoms  (<a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>). (See <a class="local">'Mild and intermittent symptoms'</a> above.)</p><p><a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">Sucralfate</a> is likely safe during pregnancy and lactation because it is poorly absorbed [<a href="#rid47">47</a>] (see <a class="local">'Surface agents and alginates'</a> above). Antacids and alginates are considered safe in pregnancy and are compatible with breastfeeding [<a href="#rid48">48</a>]. </p><p>Experience with PPIs is more limited compared with H2RAs but suggests that PPIs are probably safe in pregnancy [<a href="#rid49">49,50</a>]. Limited data are available on the secretion of PPIs in breast milk. <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">Omeprazole</a> and <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">pantoprazole</a> are secreted in low concentrations in breast milk [<a href="#rid51">51,52</a>]. However, most of this is likely destroyed by gastric acid in the infant's stomach [<a href="#rid53">53</a>]. In pregnant patients with GERD symptoms despite H2RAs, we suggest the use of omeprazole, <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">lansoprazole</a>, or pantoprazole rather than other PPIs, as they have been more widely used in pregnancy. The safety of PPIs in pregnancy has been evaluated in several studies. A meta-analysis of seven observational studies found no significant difference in the risk for major congenital birth defects, spontaneous abortions, or preterm delivery among 1530 women exposed to PPIs during pregnancy as compared with 133,410 who were not exposed to PPIs [<a href="#rid49">49</a>]. A subsequent observational study that evaluated PPI exposure in early pregnancy also found no increase in the risk of major birth defects in 3651 infants exposed to PPIs during the first trimester, as compared with 837,317 infants who had not been exposed [<a href="#rid50">50</a>]. (See <a class="local">'Proton pump inhibitors'</a> above.)</p><p>Upper endoscopy should be performed during pregnancy only if there is a strong indication (eg, significant gastrointestinal bleeding). When possible, endoscopy should be postponed until the second trimester [<a href="#rid54">54</a>]. Obstetrical staff should be closely involved and the degree of maternal and fetal monitoring should be individualized. Recommendations for procedural sedation for endoscopy in pregnant and nursing women are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2567.html" rel="external">"Gastrointestinal endoscopy in adults: Procedural sedation administered by endoscopists", section on 'Special populations'</a>.)</p><p class="headingAnchor" id="H2835252322"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116050.html" rel="external">"Society guideline links: Gastroesophageal reflux in adults"</a>.)</p><p class="headingAnchor" id="H1904407158"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15325.html" rel="external">"Patient education: Acid reflux and GERD in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15734.html" rel="external">"Patient education: H. pylori infection (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16840.html" rel="external">"Patient education: Acid reflux and GERD during pregnancy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2011.html" rel="external">"Patient education: Gastroesophageal reflux disease in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2012.html" rel="external">"Patient education: Helicobacter pylori infection and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial assessment and approach </strong>– The optimal approach to the management of gastroesophageal reflux disease (GERD) is controversial. Our management approach to patients with GERD is based on the frequency and severity of symptoms and the presence of erosive esophagitis or Barrett’s esophagus on upper endoscopy, if previously performed  (<a class="graphic graphic_algorithm graphicRef116964" href="/z/d/graphic/116964.html" rel="external">algorithm 1</a>). We suggest lifestyle and dietary modification in all patients with GERD (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Pretreatment evaluation'</a> above and <a class="local">'Lifestyle and dietary modification'</a> above and  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults", section on 'Indications'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with mild and intermittent symptoms</strong></p><p></p><p class="bulletIndent1">In patients with mild and intermittent (less than two episodes per week) symptoms of GERD who are naïve to treatment and have no evidence of erosive esophagitis or Barrett’s esophagus, we suggest as-needed low-dose histamine 2 receptor antagonists (H2RAs)  (<a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Concomitant antacids and/or sodium alginate can be used if symptoms occur less than once a week. In patients with continued symptoms, we increase the dose of H2RAs to standard dose, twice daily for a minimum of two weeks. (See <a class="local">'Antacids'</a> above and <a class="local">'Overall approach'</a> above.)</p><p></p><p class="bulletIndent1">If symptoms of GERD persist, we discontinue H2RAs and initiate once-daily proton pump inhibitors (PPIs) at a low dose (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>), and then increase to standard doses if required for symptom control  (<a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>). Once symptoms are controlled, therapy should be continued for at least eight weeks. (See <a class="local">'Histamine 2 receptor antagonist'</a> above and <a class="local">'Overall approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with erosive esophagitis</strong> – In patients with erosive esophagitis, we recommend initial acid suppressive therapy with standard-dose PPI once daily  (<a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Overall approach'</a> above and <a class="local">'Proton pump inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with frequent or severe symptoms</strong> – In patients with frequent (two or more episodes per week), severe symptoms that impair quality of life or with Barrett's esophagus, we suggest initial therapy with standard-dose PPI once daily (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Overall approach'</a> above and <a class="local">'Proton pump inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for referral</strong> – Referral to a subspecialist is warranted for patients who fail to respond to once-daily PPI therapy and patients who cannot tolerate long-term PPIs or want to discontinue therapy. (See <a class="local">'PPI refractory symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinuation of acid suppression </strong>– We discontinue acid suppression in all patients with GERD whose symptoms resolve completely with treatment, with the exception of those with erosive esophagitis on upper endoscopy and Barrett's esophagus. (See <a class="local">'Duration of acid suppression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with recurrent symptoms </strong>– In patients with recurrent symptoms within three months of discontinuing acid suppression, we continue long-term maintenance therapy with a PPI. However, if symptoms occur after three or more months, we use repeated eight-week courses of previously effective acid suppressive therapy  (<a class="graphic graphic_algorithm graphicRef116964" href="/z/d/graphic/116964.html" rel="external">algorithm 1</a>). (See <a class="local">'Recurrent symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of GERD in pregnancy</strong> – Management consists of lifestyle and dietary modification followed by pharmacologic therapy with antacids, alginates, and <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a>. In patients who fail to respond, similar to nonpregnant patients, H2RAs and then PPIs are used to control symptoms. (See <a class="local">'Pregnancy and lactation'</a> above and <a class="local">'Mild and intermittent symptoms'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1392.</a></li><li><a class="nounderline abstract_t">Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022; 117:27.</a></li><li><a class="nounderline abstract_t">Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999; 94:92.</a></li><li><a class="nounderline abstract_t">Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990; 19:683.</a></li><li><a class="nounderline abstract_t">Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121:1095.</a></li><li><a class="nounderline abstract_t">Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940.</a></li><li><a class="nounderline abstract_t">Tsuzuki T, Okada H, Kawahara Y, et al. Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. World J Gastroenterol 2011; 17:1480.</a></li><li><a class="nounderline abstract_t">Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965.</a></li><li><a class="nounderline abstract_t">Aslam M, Slaughter JC, Goutte M, et al. Nonlinear relationship between body mass index and esophageal acid exposure in the extraesophageal manifestations of reflux. Clin Gastroenterol Hepatol 2012; 10:874.</a></li><li><a class="nounderline abstract_t">Cremonini F, Locke GR 3rd, Schleck CD, et al. Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort. Neurogastroenterol Motil 2006; 18:987.</a></li><li><a class="nounderline abstract_t">Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol 1996; 31:1047.</a></li><li><a class="nounderline abstract_t">Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354:2340.</a></li><li><a class="nounderline abstract_t">Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol 2013; 108:376.</a></li><li><a class="nounderline abstract_t">DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:190.</a></li><li><a class="nounderline abstract_t">Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle Intervention in Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol 2016; 14:175.</a></li><li><a class="nounderline abstract_t">Mehta RS, Song M, Staller K, Chan AT. Association Between Beverage Intake and Incidence of Gastroesophageal Reflux Symptoms. Clin Gastroenterol Hepatol 2020; 18:2226.</a></li><li><a class="nounderline abstract_t">Eherer AJ, Netolitzky F, Högenauer C, et al. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol 2012; 107:372.</a></li><li><a class="nounderline abstract_t">Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study. Am J Gastroenterol 2014; 109:171.</a></li><li><a class="nounderline abstract_t">Mehta RS, Nguyen LH, Ma W, et al. Association of Diet and Lifestyle With the Risk of Gastroesophageal Reflux Disease Symptoms in US Women. JAMA Intern Med 2021; 181:552.</a></li><li><a class="nounderline abstract_t">Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441.</a></li><li><a class="nounderline abstract_t">Rohof WO, Bennink RJ, Smout AJ, et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11:1585.</a></li><li><a class="nounderline abstract_t">Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12:159.</a></li><li><a class="nounderline abstract_t">Sweis R, Kaufman E, Anggiansah A, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther 2013; 37:1093.</a></li><li><a class="nounderline abstract_t">Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther 2013; 38:1054.</a></li><li><a class="nounderline abstract_t">Thomas E, Wade A, Crawford G, et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2014; 39:595.</a></li><li><a class="nounderline abstract_t">Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol 2003; 18:678.</a></li><li><a class="nounderline abstract_t">Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118:S9.</a></li><li><a class="nounderline abstract_t">Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276:983.</a></li><li><a class="nounderline abstract_t">Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. Arch Intern Med 1991; 151:2394.</a></li><li><a class="nounderline abstract_t">Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol 1991; 86:1735.</a></li><li class="breakAll">Ip S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf (Accessed on December 19, 2012).</li><li><a class="nounderline abstract_t">Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004; 20:657.</a></li><li><a class="nounderline abstract_t">Hunt R. Acid suppression for reflux disease: "off-the-peg" or a tailored approach? Clin Gastroenterol Hepatol 2012; 10:210.</a></li><li><a class="nounderline abstract_t">Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798.</a></li><li><a class="nounderline abstract_t">Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011; 106:1419.</a></li><li><a class="nounderline abstract_t">Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; :CD002095.</a></li><li><a class="nounderline abstract_t">Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11 Suppl B:66B.</a></li><li><a class="nounderline abstract_t">Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005; 11:4067.</a></li><li><a class="nounderline abstract_t">Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial. Gastroenterology 2021; 160:174.</a></li><li><a class="nounderline abstract_t">Katzka DA, Kahrilas PJ. Advances in the diagnosis and management of gastroesophageal reflux disease. BMJ 2020; 371:m3786.</a></li><li><a class="nounderline abstract_t">Peura DA, Freston JW, Haber MM, et al. Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci 2009; 54:955.</a></li><li><a class="nounderline abstract_t">Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333:1106.</a></li><li><a class="nounderline abstract_t">Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients with gastrooesophageal reflux disease. Gut 1992; 33:1016.</a></li><li class="breakAll">Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on March 28, 2012).</li><li><a class="nounderline abstract_t">Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35:590.</a></li><li><a class="nounderline abstract_t">Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124:859.</a></li><li><a class="nounderline abstract_t">Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. Aliment Pharmacol Ther 2020; 51:421.</a></li><li><a class="nounderline abstract_t">Hodgkinson R, Glassenberg R, Joyce TH 3rd, et al. Comparison of cimetidine (Tagamet) with antacid for safety and effectiveness in reducing gastric acidity before elective cesarean section. Anesthesiology 1983; 59:86.</a></li><li><a class="nounderline abstract_t">Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.</a></li><li><a class="nounderline abstract_t">Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010; 363:2114.</a></li><li><a class="nounderline abstract_t">Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Can J Gastroenterol 1998; 12:225.</a></li><li><a class="nounderline abstract_t">Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. J Reprod Med 2004; 49:825.</a></li><li class="breakAll">National Health Service. Proton-pump-inhibitors for treatment of reflux in a breastfeeding mother: which is preferred? https://www.evidence.nhs.uk/search?q=%22Proton-pump-inhibitors+for+treatment+of+reflux+in+a+breastfeeding+mother%22 (Accessed on March 13, 2016).</li><li><a class="nounderline abstract_t">ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al. Guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76:18.</a></li></ol></div><div id="topicVersionRevision">Topic 2258 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18801365" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34807007" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9934737" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1977703" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The medical management of reflux esophagitis. Role of antacids and acid inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11677201" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Step-down management of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14499769" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21472108" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682569" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22226893" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nonlinear relationship between body mass index and esophageal acid exposure in the extraesophageal manifestations of reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17040409" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8938895" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gastroesophageal reflux in obese patients is not reduced by weight reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738270" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Body-mass index and symptoms of gastroesophageal reflux in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358462" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654800" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25956834" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lifestyle Intervention in Gastroesophageal Reflux Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31786327" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association Between Beverage Intake and Incidence of Gastroesophageal Reflux Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22146488" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24322837" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33393976" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association of Diet and Lifestyle With the Risk of Gastroesophageal Reflux Disease Symptoms in US Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8791975" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669304" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692690" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23600790" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24024757" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24471505" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753150" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10868896" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8805734" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1746996" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1962618" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1962618" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15352914" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22138274" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acid suppression for reflux disease: "off-the-peg" or a tailored approach?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9178669" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21537361" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23728637" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9347181" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996033" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949568" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33229333" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Advances in the diagnosis and management of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18726153" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7565948" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A comparison of five maintenance therapies for reflux esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1356887" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Three year follow up of patients with gastrooesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1356887" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Three year follow up of patients with gastrooesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200548" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610914" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31950535" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Review article: the management of heartburn during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6869899" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of cimetidine (Tagamet) with antacid for safety and effectiveness in reducing gastric acidity before elective cesarean section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19491869" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21105793" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of proton-pump inhibitors in early pregnancy and the risk of birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9582548" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15568407" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Excretion of pantoprazole in human breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15568407" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Excretion of pantoprazole in human breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22579258" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Guidelines for endoscopy in pregnant and lactating women.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
